Tue, December 20, 2022

Kostas Biliouris Upgraded (BEAM) to Buy and Increased Target to $66 on, Dec 20th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-66-on-dec-20th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Kostas Biliouris of BMO Capital, Upgraded "Beam Therapeutics Inc." (BEAM) to Buy and Increased Target from $61 to $66 on, Dec 20th, 2022.

Kostas has made no other calls on BEAM in the last 4 months.



There are 3 other peers that have a rating on BEAM. Out of the 3 peers that are also analyzing BEAM, 1 agrees with Kostas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Richard Law of "Credit Suisse" Maintained at Hold with Decreased Target to $53 on, Tuesday, November 8th, 2022


These are the ratings of the 2 analyists that currently disagree with Kostas


  • Samantha Semenkow of "Citigroup" Initiated at Strong Buy and Held Target at $62 on, Tuesday, December 13th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $81 on, Monday, November 7th, 2022